Trial Profile
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naive HIV-1 Infected Children, < 12 Years of Age
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 02 Jul 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 23 Feb 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 28 Oct 2014 Planned primary completion date changed from 1 Sep 2016 to 1 May 2018 as reported by ClinicalTrials.gov record.